» Articles » PMID: 22615292

Impact of Antibiotic MIC on Infection Outcome in Patients with Susceptible Gram-negative Bacteria: a Systematic Review and Meta-analysis

Overview
Specialty Pharmacology
Date 2012 May 23
PMID 22615292
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study was to analyze the impact of MIC values within the susceptible range of antibiotics on the outcomes of patients with Gram-negative infections. The PubMed and Scopus electronic databases were searched. We identified 13 articles (1,469 patients) that studied the impact of antibiotic MICs on the outcomes of infections; β-lactams were studied in 10 of them. Infections due to Salmonella enterica strains with high fluoroquinolone MICs were associated with more treatment failures than those due to strains with low MICs (relative risk [RR], 5.75; 95% confidence interval [CI], 1.77 to 18.71). Among non-Salmonella enterobacteriaceae, there was no difference in treatment failures depending on the MIC value (RR, 1.18; 95% CI, 0.71 to 1.97); however, a higher all-cause mortality was observed for patients infected with strains with high MICs (RR, 2.03; 95% CI, 1.05 to 3.92). More treatment failures were observed for patients infected with nonfermentative Gram-negative bacilli when strains had high MICs (RR, 5.54; 95% CI, 2.72 to 11.27). The mortality rate for patients with infections with Gram-negative nonfermentative bacilli with high MICs was also higher than for those with low MICs (RR, 2.39; 95% CI, 1.19 to 4.81). The limited available data suggest that there is an association between high MICs, within the susceptible range, and adverse outcomes for patients with Gram-negative infections.

Citing Articles

Microcin C7 as a Potential Antibacterial-Immunomodulatory Agent in the Postantibiotic Era: Overview of Its Bioactivity Aspects and Applications.

Yang F, Yang F, Huang J, Yu H, Qiao S Int J Mol Sci. 2024; 25(13).

PMID: 39000321 PMC: 11241378. DOI: 10.3390/ijms25137213.


Early Versus Late Antipseudomonal β-Lactam Antibiotic Dose Adjustment in Critically Ill Sepsis Patients With Acute Kidney Injury: A Prospective Observational Cohort Study.

Aldardeer N, Alshreef M, Alharbi E, Aljabri A, Aljawadi M, Almangour T Open Forum Infect Dis. 2024; 11(3):ofae059.

PMID: 38434610 PMC: 10906704. DOI: 10.1093/ofid/ofae059.


The Rapid Phenotypic Susceptibility Testing in Real-Life Experience: How the MIC Values Impact on Sepsis Fast Diagnostic Workflow.

Migliorisi G, Calvo M, Collura A, Di Bernardo F, Perez M, Scalia G Diagnostics (Basel). 2024; 14(1).

PMID: 38201365 PMC: 10802849. DOI: 10.3390/diagnostics14010056.


Clinical Outcomes and Adverse Effects in Septic Patients with Impaired Renal Function Who Received Different Dosages of Cefoperazone-Sulbactam.

Tai C, Tang H, Lee C Antibiotics (Basel). 2022; 11(4).

PMID: 35453212 PMC: 9026488. DOI: 10.3390/antibiotics11040460.


Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with Bacteremia.

Huang H, Wang C, Lu P, Tseng S, Wang Y, Chen T Antimicrob Agents Chemother. 2021; 65(6).

PMID: 33782006 PMC: 8315969. DOI: 10.1128/AAC.00074-21.


References
1.
Lo J, Ho K, Leung A, Tiu F, Tsang G, Lo A . Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother. 2008; 52(10):3564-7. PMC: 2565891. DOI: 10.1128/AAC.00198-08. View

2.
Bercion R, Bobossi-Serengbe G, Gody J, Beyam E, Manirakiza A, Le Faou A . Acute bacterial meningitis at the 'Complexe Pédiatrique' of Bangui, Central African Republic. J Trop Pediatr. 2007; 54(2):125-8. DOI: 10.1093/tropej/fmm075. View

3.
Tam V, Gamez E, Weston J, Gerard L, LaRocco M, Caeiro J . Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008; 46(6):862-7. DOI: 10.1086/528712. View

4.
Qureshi Z, Paterson D, Pakstis D, Adams-Haduch J, Sandkovsky G, Sordillo E . Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections. Int J Antimicrob Agents. 2010; 37(1):26-32. DOI: 10.1016/j.ijantimicag.2010.09.009. View

5.
Bhat S, Peleg A, Lodise Jr T, Shutt K, Capitano B, Potoski B . Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother. 2007; 51(12):4390-5. PMC: 2168001. DOI: 10.1128/AAC.01487-06. View